UNSPSC 51334420: Cloxypendyl dihydrochloride

This classification denotes an antipsychotic agent with the molecular formula C20H25ClN4OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JL21P191Z6, chemically known as 1-piperazineethanol, 4-(3-(3-chloro-10h-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)-, dihydrochloride, but more generally known as cloxypendyl dihydrochloride, which bears US NIH Compound Identifier 209399.

European Medicines Agency schedules cloxypendyl dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06786MIG. Most nations, for tariff purposes, schedule cloxypendyl dihydrochloride under HS 29349990. SMILES: C1CCC2C(C1)N(C3C(CC(CN3)CL)S2)CCCN4CCN(CC4)CCO.CL.CL.

UNSPSC 51334420 Cloxypendyl dihydrochloride is a Commodity code that, based on recent state and local procurement activity, does not correspond to the work actually being solicited under it. The three most recent opportunities tagged to this code—naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracting—involve purchase and distribution of broad pharmaceutical and OTC product categories, not the specific active pharmaceutical ingredient named in the code. The issuing bodies span state health agencies (Texas Health and Human Services Commission), county health departments (Seminole County, Florida), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across multiple states including Oregon). The mismatch between the code's nominal scope and actual recent procurement signals either misclassification in the opportunities themselves or a divergence between the code definition and current state and local buying practice under it.

Recent activity centers on three distinct procurement types. Seminole County issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the county community health building, with bids due July 26, 2023 (note: the source lists inconsistent dates). Texas HHS issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for self-insured pharmacy benefit management. The Minnesota Department of Administration, administering the multistate MMCAP cooperative purchasing vehicle, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Geographic activity appears concentrated in the Southeast (Florida) and Midwest (Minnesota, serving multiple states), with one Texas state-level initiative. The code shows little relevant recent activity as currently labeled.